| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vision Disorders | D014786 | 10 associated lipids |
| Multiple Myeloma | D009101 | 13 associated lipids |
| Osteoporosis | D010024 | 12 associated lipids |
| Kidney Diseases | D007674 | 29 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Otosclerosis | D010040 | 2 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Hypersensitivity, Delayed | D006968 | 43 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Calcinosis | D002114 | 5 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hein GE | [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. | 2001 | Z Rheumatol | pmid:11383046 |
| Morony S et al. | Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. | 2001 | Cancer Res. | pmid:11389072 |
| Abu-Amer Y | IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. | 2001 | J. Clin. Invest. | pmid:11390419 |
| Kon T et al. | Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. | 2001 | J. Bone Miner. Res. | pmid:11393777 |
| Fazzalari NL et al. | The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. | 2001 | J. Bone Miner. Res. | pmid:11393778 |
| Kim KJ et al. | Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. | 2001 | J. Biomed. Mater. Res. | pmid:11410897 |
| Haynes DR et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. | 2001 | Rheumatology (Oxford) | pmid:11426018 |
| Szulc P et al. | Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11443182 |
| Sakiyama H et al. | Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. | 2001 | J. Bone Miner. Metab. | pmid:11448014 |
| Choi Y et al. | Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. | 2001 | Eur. J. Immunol. | pmid:11449372 |